Glenmark gets USFDA nod for generic blood pressure medicine
Shares of Glenmark Pharmaceuticals were trading 2.17 percent up at Rs 625.20 on BSE
New Delhi, May 26 (PTI) Glenmark Pharmaceuticals today said it has received final approval from the US health regulator for its generic version Olmesartan Medoxomil Tablets, used in treatment of high blood pressure.
Representational image. Image courtesy: Agencies
The approval granted by the US Food and Drug Administration to Glenmark Pharmaceuticals Inc is for multiple strengths of 5 mg, 20 mg and 40 mg, the company said in a statement.
These are generic equivalent of Benicar Tablets of Daiichi Sankyo, Inc. Glenmark's Olmesartan Medoxomil tablets will be manufactured by the company's manufacturing facility located in Goa, India, it added.
Related Articles
Citing IMS Health sales data for the 12-month period ended March 2017, the company said Benicar achieved annual sales of about USD 950 million.
Glenmark's current portfolio consists of 115 products authorised for distribution in the US market and approximately 69 ANDA's (Abbreviated New Drug Application) pending approval with the USFDA.
Shares of Glenmark Pharmaceuticals were trading 2.17 percent up at Rs 625.20 on BSE.
also read
Now, a therapy to permanently cure high blood pressure
Scientists have developed a radical therapy that could provide a permanent cure for high blood pressure by zapping the kidneys with radio waves.
A new remedy for high blood pressure: Farting
Though most of us may find it quite embarrassing in case we were caught breaking wind, a new study has in fact suggested flatulence could help patients with high blood pressure.